Aimovig approved in Europe for migraine prevention

Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved Aimovig erenumab to prevent migraines in adults experiencing four or more per month. According to the pharma, the drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the indication in each of the EU, the U.S. and Australia.

FDA approved Aimovig in May (see "FDA Approves Aimovig as First CGRP Inhibitor for Migraines")...